mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant

被引：113

作者：

Edara, Venkata-Viswanadh ^{[1
,2
,8
]}

Manning, Kelly E. ^{[1
,2
,8
]}

Ellis, Madison ^{[1
,2
,8
]}

Lai, Lilin ^{[1
,2
,8
]}

Moore, Kathryn M. ^{[1
,2
,8
]}

Foster, Stephanie L. ^{[1
,2
,8
]}

Floyd, Katharine ^{[1
,2
,8
]}

Davis-Gardner, Meredith E. ^{[1
,2
,8
]}

Mantus, Grace ^{[1
,2
,4
]}

Nyhoff, Lindsay E. ^{[1
,2
,4
]}

Bechnak, Sarah ^{[4
]}

Alaaeddine, Ghina ^{[4
]}

Naji, Amal ^{[4
]}

Samaha, Hady ^{[4
]}

Lee, Matthew ^{[4
]}

Bristow, Laurel ^{[4
]}

Gagne, Matthew ^{[6
]}

Roberts-Torres, Jesmine ^{[6
]}

Henry, Amy R. ^{[6
]}

Godbole, Sucheta ^{[6
]}

Grakoui, Arash ^{[2
,3
,4
,8
]}

Saxton, Marybeth ^{[4
]}

Piantadosi, Anne ^{[4
,7
]}

Waggoner, Jesse J. ^{[4
]}

Douek, Daniel C. ^{[6
]}

Rouphael, Nadine ^{[4
,5
]}

Wrammert, Jens ^{[1
,2
]}

Suthar, Mehul S. ^{[1
,2
,3
,8
]}

机构：

[1] Emory Univ, Ctr Childhood Infect & Vaccines Childrens Healthc, Dept Pediat, Sch Med, Atlanta, GA 30322 USA

[2] Emory Univ, Emory Vaccine Ctr, Atlanta, GA 30322 USA

[3] Emory Univ, Dept Microbiol & Immunol, Atlanta, GA 30322 USA

[4] Emory Univ, Div Infect Dis, Dept Med, Sch Med, Atlanta, GA USA

[5] Emory Univ, Hope Clin Emory Vaccine Ctr, Decatur, GA USA

[6] Natl Inst Hlth, Natl Inst Allergy & Infect Dis, Vaccine Res Ctr, Rockville, MD USA

[7] Emory Univ, Dept Pathol & Lab Med, Sch Med, Atlanta, GA USA

[8] Yerkes Natl Primate Res Ctr, Atlanta, GA 30329 USA

来源：

CELL REPORTS MEDICINE | 2022年 / 3卷 / 02期

基金：

美国国家卫生研究院;

关键词：

antibody; B.1.1.529; booster dose; live-virus; mRNA vaccines; neutralization assay; Omicron; Omicron variant; SARS-CoV-2; vaccine induced immunity;

D O I：

10.1016/j.xcrm.2022.100529

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) omicron variant emerged in November 2021 and consists of several mutations within the spike. We use serum from mRNA-vaccinated individuals to measure neutralization activity against omicron in a live-virus assay. At 2-4 weeks after a primary series of vaccinations, we observe a 30-fold reduction in neutralizing activity against omicron. Six months after the initial two-vaccine doses, sera from naive vaccinated subjects show no neutralizing activity against omicron. In contrast, COVID-19-recovered individuals 6 months after receiving the primary series of vaccinations show a 22-fold reduction, with the majority of the subjects retaining neutralizing antibody responses. In naive individuals following a booster shot (third dose), we observe a 14-fold reduction in neutralizing activity against omicron, and over 90% of subjects show neutralizing activity. These findings show that a third dose is required to provide robust neutralizing antibody responses against the omicron variant.

引用

页数：7

共 50 条

[41] Trajectory of IgG to SARS-CoV-2 After Vaccination With BNT162b2 or mRNA-1273 in an Employee Cohort and Comparison With Natural Infection
Keshavarz, Behnam
Richards, Nathan E.
Workman, Lisa J.
Patel, Jaimin
Muehling, Lyndsey M.
Canderan, Glenda
Murphy, Deborah D.
Brovero, Savannah G.
Ailsworth, Samuel M.
Eschenbacher, Will H.
McGowan, Emily C.
Mann, Barbara J.
Nelson, Michael R.
Kadl, Alexandra
Woodfolk, Judith A.
Platts-Mills, Thomas A. E.
Wilson, Jeffrey M.
FRONTIERS IN IMMUNOLOGY, 2022, 13
[42] RISK OF SARS-COV-2 INFECTION FOLLOWING THREE DOSES OF BNT162B2 OR MRNA-1273 IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES
Raptis, C. E.
Polysopoulos, C.
Berger, C.
Ciurea, A.
Andrey, D. O.
Lescuyer, P.
Maletic, T.
Riek, M.
Scherer, A.
Von Loga, I.
Safford, J.
Lauper, K.
Moeller, B.
Vuilleumier, N.
Finckh, A.
Rubbert-Roth, A.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 539 - 539
[43] Comparative Safety of BNT162b2 and mRNA-1273 Vaccines in a Nationwide Cohort of US Veterans
Dickerman, Barbra A.
Madenci, Arin L.
Gerlovin, Hanna
Kurgansky, Katherine E.
Wise, Jessica K.
Figueroa Muniz, Michael J.
Ferolito, Brian R.
Gagnon, David R.
Gaziano, J. Michael
Cho, Kelly
Casas, Juan P.
Hernan, Miguel A.
JAMA INTERNAL MEDICINE, 2022, 182 (07) : 739 - 746
[44] Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses
Sievers, Benjamin L.
Chakraborty, Saborni
Xue, Yong
Gelbart, Terri
Gonzalez, Joseph C.
Cassidy, Arianna G.
Golan, Yarden
Prahl, Mary
Gaw, Stephanie L.
Arunachalam, Prabhu S.
Blish, Catherine A.
Boyd, Scott D.
Davis, Mark M.
Jagannathan, Prasanna
Nadeau, Kari C.
Pulendran, Bali
Singh, Upinder
Scheuermann, Richard H.
Frieman, Matthew B.
Vashee, Sanjay
Wang, Taia T.
Tan, Gene S.
SCIENCE TRANSLATIONAL MEDICINE, 2022, 14 (634)
[45] Comparative effectiveness of four COVID-19 vaccines, BNT162b2 mRNA, mRNA-1273, ChAdOx1 nCov-19 and NVX-CoV2373 against SARS-CoV-2 B.1.1.529 (Omicron) infection
Liu, Bette
Stepien, Sandrine
Qian, Jiahui
Gidding, Heather
Nicolopoulos, Katrina
Amin, Janaki
Cheng, Allen
Macartney, Kristine
VACCINE, 2023, 41 (38) : 5587 - 5591
[46] Adverse effects, perceptions and attitudes related to BNT162b2, mRNA-1273 or JNJ-78436735 SARS-CoV-2 vaccines: Population-based cohort
Oliver Bürzle
Dominik Menges
Julian D. Maier
Daniel Schams
Milo A. Puhan
Jan Fehr
Tala Ballouz
Anja Frei
npj Vaccines, 8
[47] Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera
Muik, Alexander
Lui, Bonny Gaby
Wallisch, Ann-Kathrin
Bacher, Maren
Muehl, Julia
Reinholz, Jonas
Ozhelvaci, Orkun
Beckmann, Nina
Garcia, Ramon de la Caridad Gueimil
Poran, Asaf
Shpyro, Svetlana
Finlayson, Andrew
Cai, Hui
Yang, Qi
Swanson, Kena A.
Tuereci, Oezlem
Sahin, Ugur
SCIENCE, 2022, 375 (6581) : 678 - +
[48] BNT162b2 Versus mRNA-1273 Vaccines: Comparative Analysis of Long-Term Protection Against SARS-CoV-2 Infection and Severe COVID-19 in Qatar
Chemaitelly, Hiam
Ayoub, Houssein H.
Coyle, Peter
Tang, Patrick
Hasan, Mohammad R.
Yassine, Hadi M.
Al Thani, Asmaa A.
Al-Kanaani, Zaina
Al-Kuwari, Einas
Jeremijenko, Andrew
Kaleeckal, Anvar Hassan
Latif, Ali Nizar
Shaik, Riyazuddin Mohammad
Abdul-Rahim, Hanan F.
Nasrallah, Gheyath K.
Al-Kuwari, Mohamed Ghaith
Butt, Adeel A.
Al-Romaihi, Hamad Eid
Al-Thani, Mohamed H.
Al-Khal, Abdullatif
Bertollini, Roberto
Abu-Raddad, Laith J.
INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2024, 18 (10)
[49] mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2
Darling, Tamarand L.
Ying, Baoling
Whitener, Bradley
VanBlargan, Laura A.
Bricker, Traci L.
Liang, Chieh-Yu
Joshi, Astha
Bamunuarachchi, Gayan
Seehra, Kuljeet
Schmitz, Aaron J.
Halfmann, Peter J.
Kawoaka, Yoshihiro
Elbashir, Sayda M.
Edwards, Darin K.
Thackray, Larissa B.
Diamond, Michael S.
Boon, Adrianus C. M.
MED, 2022, 3 (05): : 309 - +
[50] Adverse effects, perceptions and attitudes related to BNT162b2, mRNA-1273 or JNJ-78436735 SARS-CoV-2 vaccines: Population-based cohort
Burzle, Oliver
Menges, Dominik
Maier, Julian D.
Schams, Daniel
Puhan, Milo A.
Fehr, Jan
Ballouz, Tala
Frei, Anja
NPJ VACCINES, 2023, 8 (01)

← 1 2 3 4 5 →